AVV

Altamira Therapeutics’ Peptide-Based Delivery Platform Shown to Enhance Potency of Commonly Used Gene Delivery Method as Published in Peer-Reviewed Journal

Retrieved on: 
Wednesday, February 7, 2024
Vivisection, Peptide, Cell, RNA, Therapy, Alternative medicine, Recombinant, Safety, FDA, Dicarboxylic acid, AVV, Mouse, Food, AAV, Risk, Journal, Tissue, Cytoplasm, Melittin, Vaccine

HAMILTON, BERMUDA, Feb. 7, 2024 -- Altamira Therapeutics Ltd. (Nasdaq: CYTO) ("Altamira" or the "Company"), a company providing nanoparticle-based technology for efficient RNA delivery to extrahepatic targets, announced today the publication of a peer-reviewed article in the Journal of Integrative Medicine titled, "Melittin analog p5RHH enhances recombinant adeno-associated virus transduction efficiency". This work evaluates the use of various peptides to enhance adeno-associated virus (AAV) cell transduction and was conducted by an independent research group.1 Recombinant AAVs are commonly used as carriers to introduce nucleic acids in cells for gene therapy; several AAV-based gene therapy drugs have already been approved by the U.S. Food and Drug Administration (FDA).

Key Points: 
  • The study sought to find ways of increasing the endosomal release of AAV-based therapeutics by using peptides derived from melittin, a component of bee venom known for its ability to permeabilize biological membranes.
  • The research group evaluated 76 melittin derivatives, including p5RHH, the peptide underlying Altamira’s OligoPhore™ / SemaPhore™ nanoparticle platform for RNA delivery.
  • The scientists discovered that insertion of p5RHH into the AAV vector (p5RHH-rAAV) not only enhanced cell transduction, but also succeeded in transducing cell lines typically considered resistant to AAVs.
  • “Better transduction efficiency means that lower doses of AAVs may be used, which could lower the risk for deleterious immune responses and increase the safety of AAV-based vectors.

LogicBio Therapeutics Announces Upcoming Presentations on GeneRide Development Candidate and Multiple Advancements in AAV Manufacturing Processes at ASGCT Annual Meeting

Retrieved on: 
Wednesday, May 11, 2022
Potent, Standard of care, Capsid, Design, Generides, AVV, HEK293, Alpha-fetoprotein, Nature, Cell, AAV, Gene, Hepatocellular carcinoma, Hepatocyte, Risk, Annual report, 2021 Essex County Council election, DNA, Tissue, Society, Transfection, Liver, U.S. Securities and Exchange Commission, SEC, Saavi, DOE, Annual general meeting, Therapy, Vaccine, Pharmaceutical industry

LEXINGTON, Mass., May 11, 2022 /PRNewswire/ -- LogicBio® Therapeutics, Inc. (Nasdaq: LOGC), a clinical-stage genetic medicine company, today announced that it will present four abstracts highlighting the company's GeneRide technology in preclinical hereditary tyrosinemia type 1 (HT1) models and optimized adeno-associated virus (AAV) manufacturing processes during the American Society of Gene & Cell Therapy (ASGCT) 2022 Annual Meeting, held May 16-19, 2022, in Washington D.C. and virtually.

Key Points: 
  • LogicBio will present preclinical data from LB-401, its development candidate for the treatment of HT1.
  • The company believes that its optimized transfection process, which harnesses LogicBio's mAAVRx system, has the potential to significantly reduce per patient manufacturing costs.
  • LogicBio's downstream process improvements were made to accommodate the increased yield resulting from the company's optimized transfection process.
  • Securities and Exchange Commission(SEC) onMarch 4, 2022, and other filings that LogicBio may make with theSECin the future.